JAMP-DOMPERIDONE 10 MG
DOMPERIDONE (DOMPERIDONE MALEATE) : 10 MG · DIN 02369206 · JAMP PHARMA CORPORATION
Health Canada status: MARKETED
What is JAMP-DOMPERIDONE?
JAMP-DOMPERIDONE 10 MG contains DOMPERIDONE (DOMPERIDONE MALEATE) : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 02369206, held by JAMP PHARMA CORPORATION, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 19-Sep-2017. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is JAMP-DOMPERIDONE used for?
Symptomatic management of upper GI motility disorders (chronic/subacute gastritis, diabetic gastroparesis). Prevention of GI symptoms from dopamine agonist antiparkinsonian agents.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02369206 |
|---|---|
| Brand name | JAMP-DOMPERIDONE |
| Generic / active ingredient | DOMPERIDONE (DOMPERIDONE MALEATE) : 10 MG |
| Manufacturer | JAMP PHARMA CORPORATION |
| Strength | 10 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | A03FA03 DOMPERIDONE |
| AHFS class | 56:32.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 19-Sep-2017 |
| Original market date | 2011-10-07 00:00:00 |
How is it administered?
10 mg three times per day (max 30 mg/day). Take 15 to 30 minutes before meals. Use lowest dose for shortest duration.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly stated in provided text (refer to section 11 in full monograph).
How is it supplied?
Bottles of 500 tablets.
Contraindications
Hypersensitivity; QT prolongation; electrolyte disturbances; cardiac disease (e.g. CHF); moderate/severe liver impairment; co-administration with QT-prolonging drugs or potent CYP3A4 inhibitors.
Warnings and precautions
Increased risk of serious ventricular arrhythmias or sudden cardiac death, especially in patients >60 years or doses >30 mg/day. May elevate prolactin levels.
Is DOMPERIDONE in shortage in Canada?
A Canadian shortage report is on file for this molecule: Active — reported by SANIS HEALTH INC, last seen 30 Jul 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code A03FA03 DOMPERIDONE. 10 of 23 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| BIO-DOMPERIDONE | 10 MG | TABLET | BIOMED PHARMA | MARKETED | DIN 02445034 |
| DOMPERIDONE | 10 MG | TABLET | SANIS HEALTH INC | MARKETED | DIN 02350440 |
| DOMPERIDONE | 10 MG | TABLET | SIVEM PHARMACEUTICALS ULC | MARKETED | DIN 02238341 |
| DOMPERIDONE-10 | 10 MG | TABLET | PRO DOC LIMITEE | MARKETED | DIN 02236857 |
| JAMP DOMPERIDONE TABLETS | 10 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02543435 |
| MAR-DOMPERIDONE | 10 MG | TABLET | MARCAN PHARMACEUTICALS INC | MARKETED | DIN 02403870 |
| PRZ-DOMPERIDONE | 10 MG | TABLET | PHARMARIS CANADA INC | MARKETED | DIN 02462834 |
| TARO-DOMPERIDONE | 10 MG | TABLET | SUN PHARMA CANADA INC | MARKETED | DIN 02268078 |
| TEVA-DOMPERIDONE | 10 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 01912070 |
| APO-DOMPERIDONE | 10 MG | TABLET | APOTEX INC | DORMANT | DIN 02103613 |
Who else supplies DOMPERIDONE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. DOMPERIDONE appears in 61 registered pack listings across 10 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.